Fools rush in where angels fear to tread. Playing God with Vancouver's Supervised Injection Facility in the political borderland

International Journal of Drug Policy

Volumn 18, Issue 1, 2007, Pages 18-26

  Small, Dan ^a,b  

^a PHS Community Services Society   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Politics in Healthcare; Supervised Injection Facility

Indexed keywords

ARTICLE; CANADA; COMMUNITY ASSESSMENT; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DRUG DEPENDENCE; GOVERNMENT; HEALTH CARE; HEALTH CARE FACILITY; HUMAN; INJECTION; MEDICAL INFORMATION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; RISK MANAGEMENT; SOCIAL ASPECT; SOCIETY;

EID: 33846934768     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2006.12.013     Document Type: Note

References (43)

1. Albert T., Williams G., Legowski B., and Remis R. The economic burden of HIV/AIDS in Canada (1998), Canadian Policy Research Network Inc, Ottawa, Ont.
2. Alliance, C. (2000, 8 August). Community Alliance Mission Statement.
3. Bains C. Mom of drug addict calls on minister to keep safe-injection site open (2006), Canadian Press
4. Bains C. PM not committed to injection site (2006), Canadian Press
5. Beck U. Living in a world risk society. Economy and Society 35 (2006) 329-345
6. Bezziccheri, S., & Bazant, W. (2004). Drug and HIV/AIDS in south east Asia: A review of critical geographic areas of HIVAIDS infection among injecting drug users and of national programme responses in Cambodia, China, Lao PDR, Myanmar, Thailand and Vietnam. Regional Centre for East Asia and the Pacific, Bangkok, Thailand: United Nations Office of Drugs and Crime.
7. Drucker E. Population impact of mass incarceration under New York's rockefeller drug laws: An analysis of years of life lost. Journal of Urban Health 79 (2002) 434-435
8. Ekendahl M. The results and consequences of the compulsory treatment system. In: Tham H. (Ed). Final Swedish drug policy report (2003), Kriminologiska Institutionen 28-32
9. Elliott A.J., and Chapman S. Heroin hell their own making: Construction of heroin users in the Australian Press 1992-1997. Drug and Alcohol Review 19 (2000) 191-201
10. Giddens A. Modernity and self-identity: Self and society in the modern age (1997), Stanford University Press, Stanford (First published 1991, Cambridge: P Polity Press)
11. Goffman E. Stigma: Notes on the management of spoiled identity (1986 (1993)), Simon and Schuster Inc, New York
12. Goldberg, T. (2006). In D. Small (Ed.), Letter to the Prime Minister of Canada. Description of Swedish drug policy, Vancouver.
13. Hanvelt, R., Copley, T., Schneider, D., & Meagher, N. (1999). The economic coss and resource impacts of HIV/AIDS in BC. Community Health Research Project.
14. Heisenberg W. The physical content of quantum kinematics and mechanics: The principle of indeterminism ("Uber den anschaulichen Inhalt der quantentheoretischen Kinematik und Mechanik"). In: Wheeler J.A., and Zurek W.H. (Eds). Quantum theory and measurement (1983 (1927)), Princeton University Press, Princeton, NJ 62-84
15. Hornqvist M. Drug policy and the expansion of the prison system. In: Tham H. (Ed). Review of Swedish drug policy (2003), Kriminologiska Institutionen 47-52
16. Howell M. RCMP question safe injection site research. The Vancouver Courier (2006) 7
17. Kerr T., Stoltz J., Tyndall M., Li K., Zhang R., Montaner J., and Wood E. Impact of a medically supervised safer injection facility on community drug use patterns: A before and after study. British Medical Journal 332 (2006) 220-222
18. Kerr T., Tyndall M.W., Lai C., Montaner J.S.G., and Wood E. Drug-related overdoses within a medically supervised safer injection facility. International Journal of Drug Policy (2006)
19. Kerr T., Tyndall M.W., Li K., Montaner J.S., and Wood E. Safer injecting facility use and syringe sharing among injection drug users. Lancet 366 (2005) 316-318
20. Kuhn T. The structure of scientific revolutions (1970), University of Chicago Press, Chicago
21. Lenke L., and Olsson B. The drug policy relevance of drug related deaths. In: Tham H. (Ed). Review of Swedish drug policy (2003), Kriminologiska Institutionen
22. Levy A.R., James D., Johnston K.M., Hogg R.S., Harrigan P.R., et al. The direct costs of HIV/AIDS care. The Lancet Infectious Diseases 6 (2006) 171-176
23. MacPherson, D. (2001). A framework for action: A four-pillar approach to drug problems in Vancouver. City of Vancouver, Vancouver.
24. Mickleburgh R. Vancouver ex-mayors speak up for injection site. Globe and Mail (2006)
25. Palepu A., Tyndall M.W., Leon H., Muller J., O'Shaghnessey M.V., Schechter M.T., and Anis A.H. Hospital utilisation and costs in a cohort of injection drug users. Canadian Medical Association Journal 165 (2001) 415-420
26. Review#3. (2006). Anonymous external review of evaluation by UBC/BC. Centre for Excellence in HIV/AIDS.
27. Rothstein H., Huber M., and Gaskell G. A theory of risk colonisation: the spiralling regulatory logics of societal and institutional risk. Economy and Society 35 (2006) 911-1112
28. Service DaOCA. (2006, July 20). Quotables on SIS and HR; Letters.
29. Small D. Mental illness, addiction and the Supervised Injection Facility. Visions: BC's Mental Health and Addictions Journal 2 (2004) 37-39
30. Small D., and Drucker E. Policy makers ignoring science and scientists ignoring policy: The medical ethical challenges of heroin treatment. Harm Reduction Journal 3 (2006) 1-14
31. Small D., Palepu A., and Tyndal M.W. The establishment of North America's first state sanctioned Supervised Injection Facility: A case study in culture change. International Journal of Drug Policy 17 (2006) 73-82
32. Tham H. Drug policy and trends in problematic drug use in Sweden. In: Tham H. (Ed). Review of Swedish drug policy (2003), Kriminologiska Institutionen 5-18
33. Tham, H. (2006). In D. Small (Ed.), Concerning Vancouver's Supervised Injection Facility. Correspondence regarding Swedish drug policy.
34. Tyndall M.W., Kerr T., Zhang R., King E., Montaner J.G., and Wood E. Attendance, drug use patterns, and referrals made from North America's first Supervised Injection Facility. Drug and Alcohol Dependence (2005)
35. WHO. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users (2004), World Health Organisation, Geneva
36. Wood E., Tyndall M.W., Lai C., Montaner J.S.G., and Kerr T. Impact of a medically Supervised Safer Injecting Facility on drug dealing and other drug-related crime. Substance Abuse Treatment, Prevention and Policy 1 (2006) 1-4
37. Wood E., Tyndall M.W., Li K., Lloyd-Smith E., Small W., Montaner J.S.G., and Kerr T. Do Supervised Injecting Facilities attract higher-risk injection drug users?. American Journal of Preventive Medicine 29 (2005) 126-130
38. Wood E., Tyndall M.W., Qui Z., Zhang R., Montaner J.S., and Kerr T. Service uptake and characteristics of injection drug users utilizing North America's first medically Supervised Safer Injection Facility. American Journal of Public Health 96 (2006) 770-773
39. Wood E., Tyndall M.W., Stoltz J., Small W., Lloyd-Smith E., Zhang R., Montaner J.S.G., and Kerr T. Factors associated with syringe sharing among users of a medically Supervised Injecting Facility. American Journal of Infectious Diseases 1 (2005) 50-54
40. Wood E., Tyndall M.W., Stoltz J., Small W., Zhang R., O'Connell J., Montaner J.S.G., and Kerr T. Safer injecting education for HIV prevention within a medically Supervised Safer Injecting Facility. International Journal of Drug Policy 16 (2005) 281-284
41. Wood E., Tyndall M.W., Zhang R., Stoltz J., Lai C., Montaner J.S.G., and Kerr T. Attendance at Supervised Injecting Facilities and use of detoxification services. New England Journal of Medicine 354 (2006) 2512-2514
42. Woods A. Ottawa ignores support for injection sites: Harper government froze new sites even though own poll showed backing for them. Vancouver Sun (2006) A1-A2
43. Yazdanpanah Y., Goldie S.J., Losina E., Weinstein M.C., Lebrun T., Paltiel A.D., Seage III G.R., Leblanc G., Ajana F., Kimmel A.D., Zhang H., Salamon R., Mouton Y., and Freedberg K.A. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antiretroviral Therapy 7 (2002) 257-266